Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Leuk Lymphoma. 2016 May 17;57(10):2409–2416. doi: 10.3109/10428194.2016.1161186

Figure 4. Tris-DBA overcomes stromal protection of CLL B-cells.

Figure 4

CLL B-cells (1.0 × 106/ml) were cultured with human primary bone marrow stroma for 24 h as described by us before, where Tris-DBA was then added at increasing concentrations (0, 1, 2.5, 7.5 and 10 μM), and then CLL B-cells were harvested and analyzed for apoptosis by staining with annexin/PI.